Literature DB >> 7635518

An aberrant splicing using a 3' cryptic splice site within the CH1 exon induces truncated mu-chain production.

T Komori1, H Sugiyama.   

Abstract

AT8--1-12--5-1, an Abelson virus-transformed immature B-cell line, produced truncated mu-chains. Sequencing analysis of the mu-expressed allele revealed that the variable region was an out-of-frame VH7183-DSP2-JH3 complex. Two cDNA clones (5-1 cDNA1 and 5-1 cDNA2) derived from the transcripts of the mu-expressed allele were cloned and sequenced. Sequencing analysis of 5-1 cDNA1 revealed that the VH7183-DSP2-JH3 sequence jointed to the CH1 exon at 136 bp, 3' from the 5' end of the CH1 exon, resulting in the change of the reading frame from out-of-frame to in-frame. On the other hand, sequencing analysis of 5-1 cDNA2, which appeared to have derived from intron-containing premature mRNA, revealed that the J-C intron sequence joined to the CH1 exon at 110 bp 3' from the 5' end of the CH1 exon, indicating the deletion of 109 bp including the 3' splice site of the CH1 exon. These results demonstrate that the deletion of the authentic 3' splice site of the CH1 exon induced activation of the cryptic splice site within the CH1 exon. This was followed by splicing of the variable region to the CH1 exon at the cryptic splice site at 136 bp 3' from the 5' end of the CH1 exon, resulting in the change of the reading frame from out-of-frame to in-frame, followed by the truncated mu-chain production.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7635518      PMCID: PMC1384041     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  14 in total

1.  Production of an abnormal mu chain with a shortened VHIV subgroup variable region in a Burkitt's lymphoma cell line.

Authors:  M Cogné; S Mounir; T Mahdi; J L Preud'homme; F Nau; P Guglielmi
Journal:  Mol Immunol       Date:  1990-09       Impact factor: 4.407

2.  Relationship between the rearrangement of immunoglobulin genes, the appearance of a B lymphocyte antigen, and immunoglobulin synthesis in murine pre-B cell lines.

Authors:  H Sugiyama; S Akira; N Yoshida; S Kishimoto; Y Yamamura; P Kincade; T Honjo; T Kishimoto
Journal:  J Immunol       Date:  1982-06       Impact factor: 5.422

3.  Nucleotide sequences of immunoglobulin mu heavy chain deletion mutants.

Authors:  W O Baczynsky; S Sugii; H Murialdo; N Pennell; C Filkin; N Hozumi; M J Shulman
Journal:  Nucleic Acids Res       Date:  1983-11-11       Impact factor: 16.971

4.  An immunoglobulin deletion mutant with implications for the heavy-chain switch and RNA splicing.

Authors:  W Dunnick; T H Rabbitts; C Milstein
Journal:  Nature       Date:  1980-08-14       Impact factor: 49.962

5.  A catalogue of splice junction sequences.

Authors:  S M Mount
Journal:  Nucleic Acids Res       Date:  1982-01-22       Impact factor: 16.971

6.  Multiple genomic defects result in an alternative RNA splice creating a human gamma H chain disease protein.

Authors:  P Guglielmi; A Bakhshi; M Cogne; M Seligmann; S J Korsmeyer
Journal:  J Immunol       Date:  1988-09-01       Impact factor: 5.422

7.  Gamma heavy chain disease in man. Genomic sequence reveals two noncontiguous deletions in a single gene.

Authors:  A Alexander; I Anicito; J Buxbaum
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

8.  Loss of a consensus splice signal in a mutant immunoglobulin gene eliminates the CH1 domain exon from the mRNA.

Authors:  C R Brandt; S L Morrison; B K Birshtein; C Milcarek
Journal:  Mol Cell Biol       Date:  1984-07       Impact factor: 4.272

9.  Molecular basis of the cell-surface expression of immunoglobulin mu chain without light chain in human B lymphocytes.

Authors:  B A Pollok; R Anker; P Eldridge; L Hendershot; D Levitt
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

10.  Deletions in immunoglobulin mu chains.

Authors:  G Köhler; M J Potash; H Lehrach; M J Shulman
Journal:  EMBO J       Date:  1982       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.